CN112040944A - 用于治疗癌症的组合 - Google Patents

用于治疗癌症的组合 Download PDF

Info

Publication number
CN112040944A
CN112040944A CN201980028857.5A CN201980028857A CN112040944A CN 112040944 A CN112040944 A CN 112040944A CN 201980028857 A CN201980028857 A CN 201980028857A CN 112040944 A CN112040944 A CN 112040944A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
cancer
azd5991
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980028857.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·博伊科
J·奇达多
L·德鲁
T·普罗伊亚
M·桑马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN112040944A publication Critical patent/CN112040944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980028857.5A 2018-04-30 2019-04-29 用于治疗癌症的组合 Pending CN112040944A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30
US62/664356 2018-04-30
PCT/IB2019/053491 WO2019211721A1 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Publications (1)

Publication Number Publication Date
CN112040944A true CN112040944A (zh) 2020-12-04

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980028857.5A Pending CN112040944A (zh) 2018-04-30 2019-04-29 用于治疗癌症的组合

Country Status (14)

Country Link
US (1) US20210030718A1 (https=)
EP (1) EP3787620A1 (https=)
JP (1) JP2021522246A (https=)
KR (1) KR20210005182A (https=)
CN (1) CN112040944A (https=)
AU (1) AU2019263026B2 (https=)
BR (1) BR112020022020A2 (https=)
CA (1) CA3097486A1 (https=)
EA (1) EA202092540A1 (https=)
MA (1) MA52499A (https=)
MX (1) MX2020011453A (https=)
SG (1) SG11202010528XA (https=)
TW (1) TW202014184A (https=)
WO (1) WO2019211721A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158321A1 (en) * 2019-11-04 2021-05-14 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
JP2023510135A (ja) * 2019-12-18 2023-03-13 ゼノ マネジメント，インコーポレイテッド 大環状化合物
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022853A1 (en) * 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
CN107056786A (zh) * 2016-10-14 2017-08-18 苏州明锐医药科技有限公司 阿卡替尼的制备方法
WO2017182625A1 (en) * 2016-04-22 2017-10-26 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022853A1 (en) * 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
WO2017182625A1 (en) * 2016-04-22 2017-10-26 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer
CN107056786A (zh) * 2016-10-14 2017-08-18 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
US20210030718A1 (en) 2021-02-04
EP3787620A1 (en) 2021-03-10
CA3097486A1 (en) 2019-11-07
JP2021522246A (ja) 2021-08-30
AU2019263026B2 (en) 2022-06-30
EA202092540A1 (ru) 2021-03-17
WO2019211721A1 (en) 2019-11-07
MX2020011453A (es) 2020-12-07
BR112020022020A2 (pt) 2021-02-02
MA52499A (fr) 2021-04-14
SG11202010528XA (en) 2020-11-27
KR20210005182A (ko) 2021-01-13
TW202014184A (zh) 2020-04-16
AU2019263026A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
US20250221961A1 (en) Pharmaceutical Combinations For The Treatment Of Cancer
KR20240167633A (ko) 종양 치료용 약학 조성물
CN112040944A (zh) 用于治疗癌症的组合
US20090054415A1 (en) Combinations, methods and compositions for treating cancer
CN104363913A (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
US10463649B2 (en) Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
JP2019511526A (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
US20140235630A1 (en) Compositions and methods for the treatment of proliferative diseases
CN101808636A (zh) 黑色素瘤的治疗
AU2021255084B2 (en) Breast cancer therapeutic agent
TWI810397B (zh) 治療癌症之方法
JP6445082B2 (ja) ５’−ヒドロキシ−５−ニトロ−インジルビン−３’−オキシムを有効成分として含有する乳がん治療剤
CN108721279B (zh) 包含5′-羟基-5-硝基-靛玉红-3′-肟作为活性成分的乳腺癌治疗剂
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
HK40041700A (en) Combinations for treating cancer
WO2023158610A1 (en) Hdac inhibitor oki-179 in combination with binimetinib for the treatment of cancer
US20240238220A1 (en) Methods for treating cancers
Tonogai Identifying the basis for anticancer synergy with PAC-1, with applications to meningioma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041700

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201204